Compare TH & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | HROW |
|---|---|---|
| Founded | 1978 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2017 | 2008 |
| Metric | TH | HROW |
|---|---|---|
| Price | $20.48 | $30.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $25.20 | ★ $65.00 |
| AVG Volume (30 Days) | ★ 1.9M | 486.5K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $320,635,000.00 | N/A |
| Revenue This Year | $36.96 | $28.81 |
| Revenue Next Year | $71.08 | $53.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.97 | $28.54 |
| 52 Week High | $21.76 | $54.98 |
| Indicator | TH | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 27.10 |
| Support Level | $18.43 | $28.54 |
| Resistance Level | $20.66 | $35.43 |
| Average True Range (ATR) | 0.84 | 1.25 |
| MACD | -0.17 | -0.21 |
| Stochastic Oscillator | 43.85 | 11.48 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.